Patatin-like phospholipase 3 (rs738409) gene polymorphism is associated with increased liver enzymes in obese adolescents and metabolic syndrome in all ages

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 1, 2015, Pages 99-105

  Mangge, H ^a,b   Baumgartner, B G ^c   Zelzer, S ^a   Pruller F ^a   Schnedl, W J ^d   Reininghaus, E Z ^a   Haybaeck, J ^a   Lackner, C ^a   Stauber, R ^a   Aigner, E ^c   Weghuber, D ^c  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b BIOTECHMED GRAZ   (Austria)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

^d General Practice for Internal Medicine   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; LIVER ENZYME; PATATIN LIKE PHOSPHOLIPASE 3; PHOSPHOLIPASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPONUTRIN, HUMAN; MEMBRANE PROTEIN; TRIACYLGLYCEROL LIPASE;

ADOLESCENT; ADULT; ALLELE; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CAROTID ARTERY; CAUCASIAN; CHILD; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HIP CIRCUMFERENCE; HOMOZYGOTE; HUMAN; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; OBSERVATIONAL STUDY; PNPLA3 GENE; PRIORITY JOURNAL; SCHOOL CHILD; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WAIST HIP RATIO; AGED; CASE CONTROL STUDY; COMPLICATION; GENETICS; LIFESTYLE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PROSPECTIVE STUDY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; CHILD; FEMALE; GENOTYPE; HETEROZYGOTE; HUMANS; LIFE STYLE; LIPASE; MALE; MEMBRANE PROTEINS; METABOLIC SYNDROME X; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84930677627     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13232     Document Type: Article

References (31)

1. Mangge H, Almer G, Truschnig-Wilders M, Schmidt A, Gasser R, Fuchs D,. Inflammation, adiponectin, obesity and cardiovascular risk. Curr Med Chem 2010; 17: 4511-20.
2. Marzuillo P, del Giudice EM, Santoro N,. Pediatric non-alcoholic fatty liver disease: new insights and future directions. World J Hepatol 2014; 6: 217-25.
3. Mitchel EB, Lavine JE,. Review article: the management of paediatric nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2014; 40: 1155-70.
4. Vernon G, Baranova A, Younossi ZM,. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-85.
5. Lin YC, Chang PF, Hu FC, Yang WS, Chang MH, Ni YH,. A common variant in the PNPLA3 gene is a risk factor for non-alcoholic fatty liver disease in obese Taiwanese children. J Pediatr 2011; 158: 740-4.
6. Valenti L, Nobili V,. PNPLA3 I148M polymorphism and liver damage in obese children. J Pediatr 2011; 159: 876.
7. Santoro N, Kursawe R, D'Adamo E, et al,. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52: 1281-90.
8. Stojkovic IA, Ericson U, Rukh G, Riddestrale M, Romeo S, Orho-Melander M,. The PNPLA3 Ile148Met interacts with overweight and dietary intakes on fasting triglyceride levels. Genes Nutr 2014; 9: 388.
9. He S, McPhaul C, Li JZ, et al,. A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis. J Biol Chem 2010; 285: 6706-15.
10. Huang Y, Cohen JC, Hobbs HH,. Expression and characterization of a PNPLA3 protein isoform (I148M) associated with nonalcoholic fatty liver disease. J Biol Chem 2011; 286: 37085-93.
11. Shen J, Wong GL, Chan HL, et al,. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther 2014; 39: 532-9.
12. Lallukka S, Sevastianova K, Perttila J, et al,. Adipose tissue is inflamed in NAFLD due to obesity but not in NAFLD due to genetic variation in PNPLA3. Diabetologia 2013; 56: 886-92.
13. Shen J, Wong GL, Chan HL, et al,. PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2015; 30: 139-46.
14. Marzuillo P, Grandone A, Perrone L, del Giudice EM,. Weight loss allows the dissection of the interaction between abdominal fat and PNPLA3 (adiponutrin) in the liver damage of obese children. J Hepatol 2013; 59: 1143-4.
15. Romeo S, Sentinelli F, Cambuli VM, et al,. The 148M allele of the PNPLA3 gene is associated with indices of liver damage early in life. J Hepatol 2010; 53: 335-8.
16. Mai M, Kovacs P, Stumvoll M, Rosendahl J, Tonjes A,. Association between genetic variants in PNPLA3 and serum adiponectin. Liver Int 2015; 35: 679-80
17. Stefan N, Stumvoll M, Vozarova B, et al,. Plasma adiponectin and endogenous glucose production in humans. Diabetes Care 2003; 26: 3315-9.
18. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH,. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000; 320: 1240-3.
19. Alberti KG, Zimmet P, Shaw J,. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-80.
20. Zimmet P, MM Alberti KG, Serrano Rios M,. A new international diabetes federation worldwide definition of the metabolic syndrome: the rationale and the results. Rev Esp Cardiol 2005; 58: 1371-6.
21. Mangge H, Zelzer S, Meinitzer A, et al,. 25OH-vitamin D3 levels in obesity and metabolic syndrome-unaltered in young and not correlated to carotid IMT in all ages. Curr Pharm Design 2015; [Epub ahead of print] PMID: 25557634.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-9.
23. Dam-Larsen S, Franzmann M, Andersen IB, et al,. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004; 53: 750-5.
24. Yilmaz Y,. Review article: is non-alcoholic fatty liver disease a spectrum, or are steatosis and non-alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Ther 2012; 36: 815-23.
25. Husain N, Blais P, Kramer J, et al,. Nonalcoholic fatty liver disease (NAFLD) in the Veterans Administration population: development and validation of an algorithm for NAFLD using automated data. Aliment Pharmacol Ther 2014; 40: 949-54.
26. Pingitore P, Pirazzi C, Mancina RM, et al,. Recombinant PNPLA3 protein shows triglyceride hydrolase activity and its I148M mutation results in loss of function. Biochim Biophys Acta 2014; 1841: 574-80.
27. Pirazzi C, Adiels M, Burza MA, et al,. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro. J Hepatol 2012; 57: 1276-82.
28. Pirazzi C, Valenti L, Motta BM, et al,. PNPLA3 has retinyl-palmitate lipase activity in human hepatic stellate cells. Hum Mol Genet 2014; 23: 4077-85.
29. Petta S, Vanni E, Bugianesi E, et al,. PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C. Aliment Pharmacol Ther 2015; 41: 939-48.
30. Romeo S, Sentinelli F, Dash S, et al,. Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent. Int J Obes 2010; 34: 190-4.
31. Zhang L, You W, Zhang H, et al,. PNPLA3 Polymorphisms (rs738409) and non-alcoholic fatty liver disease risk and related phenotypes: a meta-analysis. J Gastroenterol Hepatol 2015; 30: 821-9.